The company said all three doses of the experimental drug, TX-004HR,
reduced vaginal pain during intercourse in women who had undergone
menopause.
Vaginal pain, clinically called dyspareunia, is one of the biggest
symptoms of vulvar and vaginal atrophy, a common and underreported
condition associated with decreased estrogen in post-menopausal
women.
The three doses of the drug also increased the number of certain
kinds of cells in the vagina, TherapeuticsMD said.
The company said there were no safety concerns associated with the
gel.
TherapeuticsMD, which is conducting complete safety and efficacy
data from the study, said it expected to file for marketing
application in the first half of 2016.
The company's shares closed down 5 percent in regular trading on
Monday. They were up 53 percent at $9.95 after the bell.
[to top of second column] |
![](http://archives.lincolndailynews.com/2015/Dec/08/images/ads/current/mcquellons_lda_christmas_2015.png)
(Reporting by Vidya L Nathan in Bengaluru; Editing by Maju Samuel
and Savio D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
![](http://archives.lincolndailynews.com/2015/Dec/08/images/ads/current/directory_buttons.png) |